GILD

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Gilead Sciences, Inc. for the quarter ended March 31, 2005. Gilead is a biopharmaceutical company focused on developing and commercializing therapeutics for infectious diseases, primarily HIV, Hepatitis B, and fungal infections. The company operates globally with marketing in eleven countries and relies heavily on collaborative agreements for the distribution of products like Tamiflu and Macugen.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 39% year-over-year, driven primarily by a 45% increase in product sales. HIV product sales grew 47% to $301.5 million, fueled by the launch and adoption of Truvada and growth in Viread and Emtriva.
• Product Performance: Hepsera sales surged 125% to $42.7 million due to European launches and U.S. prescription growth. AmBisome sales rose 5% to $54.2 million despite competitive pressure.
• R&D Expenses: Increased 20% to $70.4 million. This was largely due to a $15.0 million upfront license fee paid to Japan Tobacco for an HIV integrase inhibitor and increased costs for hepatitis C collaborations.
• SG&A Expenses: Increased 13% to $80.1 million, attributed to higher headcount, expanded sales/marketing activities, and foreign patent legal costs.
• Non-Recurring Items: Q1 2004 included a $20.6 million gain on Eyetech warrants, which was absent in Q1 2005. Conversely, Q1 2005 included a $7.0 million milestone payment from Eyetech for Macugen sales.

Guidance, Outlook, and Risks

Management Guidance (Full Year 2005)

• HIV Product Sales: Expected to range between $1.225 billion and $1.275 billion.
• AmBisome Sales: Expected to range between $200 million and $210 million.
• Hepsera Sales: Expected to range between $160 million and $180 million.
• R&D Expenses: Expected to range between $250 million and $270 million (includes the Japan Tobacco fee).
• SG&A Expenses: Expected to range between $350 million and $370 million.
• Capital Expenditures: Expected to range between $55 million and $65 million.
• Gross Margin: Expected to remain between 85% and 86%.

Key Risks and Contingencies

• Competition: Significant competition from larger firms (e.g., GSK for HIV products; Merck and Pfizer for AmBisome) poses a risk to market share and pricing.
• Regulatory & Safety: Ongoing clinical trials and post-market surveillance may reveal safety issues or resistance, potentially limiting sales. Regulatory approval for new formulations (e.g., Truvada/Sustiva combination) is not guaranteed.
• Legal Proceedings: Gilead is a defendant in multi-district litigation regarding Medicaid reimbursement pricing and a consolidated securities class action lawsuit. Outcomes are unpredictable, and no amounts have been accrued.
• Collaboration Risks: Reliance on partners (Roche, BMS, Astellas, etc.) for sales and development introduces risks regarding resource allocation and contract enforcement.
• Accounting Changes: The company expects to adopt SFAS 123R (Share-Based Payment) on January 1, 2006, which will likely have a material impact on reported earnings and cash flows.

Investor Verification Checklist

• Verify the sustainability of the 47% growth in HIV product sales, specifically the transition of patients from Viread to Truvada.
• Monitor the status of the Truvada/Sustiva fixed-dose combination regulatory filings and potential delays.
• Assess the impact of the $15.0 million Japan Tobacco license fee on future R&D burn rates and pipeline progress.
• Review updates on the consolidated securities class action lawsuit and Medicaid pricing litigation for potential financial exposure.
• Track the adoption timeline and financial impact of SFAS 123R effective January 1, 2006.
• Confirm the stability of European reimbursement rates and payment collection from government entities, particularly in Greece, Italy, Portugal, and Spain.